Literature DB >> 2005926

A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome.

P Brown1, P D Thompson, J C Rothwell, B L Day, C D Marsden.   

Abstract

We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred in the 10 patients.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2005926     DOI： 10.1002/mds.870060114

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  4 in total

1.  Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.

Authors:  J Semba; M Doheny; P N Patsalos; G Sarna; G Curzon
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

Authors:  J Semba; G Curzon; P N Patsalos
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

3.  A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug.

Authors:  M H Doheny; S Nagaki; P N Patsalos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

4.  Stiff-person Syndrome.

Authors:  Olavo M. Vasconcelos; Marinos C. Dalakas
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.